Adamas Pharmaceuticals, Inc focuses on the discovery, development, and commercialization of medicines for patients suffering from chronic neurologic disorders. The company offers GOCOVRI, an extended release capsule for the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone510-450-3500
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$34.05 million
Profitability
Miscellaneous
Employees159
Next Earnings Date11/7/2019 (Estimated)
OptionableOptionable
Adamas Pharmaceuticals (NASDAQ:ADMS) Frequently Asked Questions
What is Adamas Pharmaceuticals' stock symbol?
Adamas Pharmaceuticals trades on the NASDAQ under the ticker symbol "ADMS."
How were Adamas Pharmaceuticals' earnings last quarter?
Adamas Pharmaceuticals Inc (NASDAQ:ADMS) issued its earnings results on Thursday, August, 8th. The specialty pharmaceutical company reported ($0.90) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.98) by $0.08. The specialty pharmaceutical company had revenue of $12.69 million for the quarter, compared to the consensus estimate of $12.62 million. Adamas Pharmaceuticals had a negative net margin of 241.41% and a negative return on equity of 149.97%. View Adamas Pharmaceuticals' Earnings History.
When is Adamas Pharmaceuticals' next earnings date?
What price target have analysts set for ADMS?
10 brokers have issued 1 year target prices for Adamas Pharmaceuticals' stock. Their forecasts range from $5.00 to $55.00. On average, they expect Adamas Pharmaceuticals' stock price to reach $18.44 in the next twelve months. This suggests a possible upside of 363.4% from the stock's current price. View Analyst Price Targets for Adamas Pharmaceuticals.
What is the consensus analysts' recommendation for Adamas Pharmaceuticals?
10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Adamas Pharmaceuticals in the last year. There are currently 2 sell ratings, 3 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Adamas Pharmaceuticals.
Has Adamas Pharmaceuticals been receiving favorable news coverage?
Media stories about ADMS stock have trended somewhat negative on Saturday, InfoTrie Sentiment Analysis reports. The research group identifies negative and positive press coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Adamas Pharmaceuticals earned a coverage optimism score of -1.5 on InfoTrie's scale. They also gave news articles about the specialty pharmaceutical company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View News Stories for Adamas Pharmaceuticals.
Are investors shorting Adamas Pharmaceuticals?
Adamas Pharmaceuticals saw a decline in short interest in September. As of September 30th, there was short interest totalling 2,010,000 shares, a decline of 16.6% from the August 30th total of 2,410,000 shares. Based on an average daily trading volume, of 540,000 shares, the days-to-cover ratio is currently 3.7 days. Currently, 9.2% of the shares of the stock are short sold. View Adamas Pharmaceuticals' Current Options Chain.
Who are some of Adamas Pharmaceuticals' key competitors?
Some companies that are related to Adamas Pharmaceuticals include Aurinia Pharmaceuticals (AUPH), Progenics Pharmaceuticals (PGNX), Beyondspring (BYSI), Evolus (EOLS), Synthorx (THOR), Crinetics Pharmaceuticals (CRNX), Collegium Pharmaceutical (COLL), Stemline Therapeutics (STML), Syros Pharmaceuticals (SYRS), Verrica Pharmaceuticals (VRCA), Magenta Therapeutics (MGTA), Avedro (AVDR), Dermira (DERM), XBiotech (XBIT) and AMAG Pharmaceuticals (AMAG).
What other stocks do shareholders of Adamas Pharmaceuticals own?
Who are Adamas Pharmaceuticals' key executives?
Adamas Pharmaceuticals' management team includes the folowing people:
- Dr. Gregory T. Went, Co-Founder, Chairman & CEO (Age 55)
- Mr. Alfred G. Merriweather, Chief Financial Officer (Age 65)
- Mr. Christopher B. Prentiss, Chief Accounting Officer (Age 44)
- Ashleigh Barreto, Director of Corp. Communications & Investor Relations
- Ms. Jennifer J. Rhodes, Chief Bus. Officer, Gen. Counsel, Chief Compliance Officer & Corp. Sec. (Age 49)
How do I buy shares of Adamas Pharmaceuticals?
Shares of ADMS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Adamas Pharmaceuticals' stock price today?
One share of ADMS stock can currently be purchased for approximately $3.98.
How big of a company is Adamas Pharmaceuticals?
Adamas Pharmaceuticals has a market capitalization of $110.53 million and generates $34.05 million in revenue each year. The specialty pharmaceutical company earns $-131,000,000.00 in net income (profit) each year or ($4.87) on an earnings per share basis. Adamas Pharmaceuticals employs 159 workers across the globe.View Additional Information About Adamas Pharmaceuticals.
What is Adamas Pharmaceuticals' official website?
How can I contact Adamas Pharmaceuticals?
Adamas Pharmaceuticals' mailing address is 1900 POWELL ST. SUITE 1000, EMERYVILLE CA, 94608. The specialty pharmaceutical company can be reached via phone at 510-450-3500 or via email at [email protected]
MarketBeat Community Rating for Adamas Pharmaceuticals (NASDAQ ADMS)
MarketBeat's community ratings are surveys of what our community members think about Adamas Pharmaceuticals and other stocks. Vote "Outperform" if you believe ADMS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ADMS will underperform the S&P 500 over the long term. You may vote once every thirty days.
